Bayer, J&J’s Xarelto fails to hit PhIII targets

Bayer and Johnson & Johnson’s plans to expand the scope of blood thinner Xarelto have hit a setback after the drug failed to hit targets in two studies in venous thromboembolism and heart failure studies.Original Article